Investment Thesis
Kewaunee Scientific exhibits strong revenue growth (+17.3% YoY) and maintains robust financial health with low leverage (0.27x debt/equity) and positive free cash flow, but profitability deterioration is concerning—net income declined 9.7% YoY despite revenue gains, indicating operational efficiency challenges in this low-margin business.
Strengths
- Strong top-line growth of 17.3% demonstrates market demand for lab equipment
- Fortress balance sheet: 0.27x debt/equity with 2.18x current ratio and $9.9M cash
- Positive free cash flow generation of $14.7M with exceptional interest coverage of 15.8x
- Moderate capital intensity (CapEx of $3.9M) enables cash reinvestment flexibility
Risks
- Profitability declining sharply (-9.7% net income YoY despite +17.3% revenue growth) signals margin compression and operational deleverage
- Operating margin of 5.9% and net margin of 3.4% are critically low, limiting financial flexibility and downside protection
- Gross margin of 28.5% combined with failing to expand EBIT suggests inability to pass through costs or control operating expenses
- EPS down 15.9% YoY indicates shareholder value destruction despite growth, raising sustainability questions
Key Metrics to Watch
- Gross margin trend and cost of goods sold ratio—verify margin compression is not structural
- Operating expense ratio and operating leverage—confirm cost discipline can be regained
- Free cash flow conversion and working capital management—essential to validate cash generation quality amid profit decline
Financial Metrics
Revenue
282.0M
Net Income
9.6M
EPS (Diluted)
$3.22
Free Cash Flow
14.7M
Total Assets
178.3M
Cash
10.0M
Profitability Ratios
Gross Margin
28.5%
Operating Margin
5.9%
Net Margin
3.4%
ROE
12.9%
ROA
5.4%
FCF Margin
5.2%
Balance Sheet & Liquidity
Current Ratio
2.18x
Quick Ratio
1.55x
Debt/Equity
0.27x
Debt/Assets
56.9%
Interest Coverage
15.80x
Long-term Debt
20.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-07-30T06:02:37.400870 |
Data as of: 2026-04-30 |
Powered by Claude AI